United States · Platforms & data · MarketBeat

WAVE Life Sciences Highlights Obesity Data, FDA-Aligned RNA Editing Path

Published by MarketBeat · United States 1 h ago

WAVE Life Sciences (NASDAQ:WVE) outlined progress across its obesity-focused siRNA program and RNA editing pipeline during a Chardan discussion, with President and CEO Paul Bolno…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

MarketWatch

My father-in-law, 81, sold his $75,000 home and paid off his daughter’s $50,000 debt. What happens to him now?

Investing.com

Tesla Asian supplier shares fall after mixed Q3 earnings, cautious outlook

Stocktwits

IBM Stock Heads For Best Week Since June: CEO Says ‘Q2 Softness Was Timing Rather Than Demand’ After Q3 Beat, Sees Infrastructure Momentum

Yahoo Finance

How Investors Are Reacting To Aya Gold & Silver Stock After Boumadine PEA Update

TheStreet

KFC rolls out 13 days of Halloween deals, but there’s a catch

CNBC